Times Reports on Successful Proxy Contest for Biotechnology Company
The New York Times reported on the resolution between Avigen, a bio-tech company, and Biotechnology Value Fund, Olshan's client and Avigen's largest shareholder. Avigen agreed to Biotechnology Value Fund's demand to dissolve and to liquidate in the aftermath of its failed drug trial. The initial controversy was extensively covered by The New York Times, Greenbackd and FierceBiotech.
Adam W. Finerman's team representing Biotechnology Value Fund included Jason W. Soncini, Jesse A. Hofrichter and Ryan S. Replogle.